<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="34745"><DrugName>ozarelix</DrugName><DrugNamesKey><Name id="42841495">ozarelix</Name></DrugNamesKey><DrugSynonyms><Name><Value>D-63153</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>SPI-153</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>ozarelix</Value><Types><Type>INN</Type></Types></Name><Name><Value>AEZS-106</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>295350-45-7</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="15623">ASTA Medica AG</CompanyOriginator><CompaniesPrimary><Company id="18535">Nippon Kayaku Co Ltd</Company><Company id="24232">Spectrum Pharmaceuticals Inc</Company></CompaniesPrimary><CompaniesSecondary><Company id="15623">ASTA Medica AG</Company><Company id="22711">AEterna Zentaris Inc</Company><Company id="29069">Zentaris GmbH</Company><Company id="29750">Baxter Oncology GmbH</Company></CompaniesSecondary><CrossReferences><SourceEntity id="34745" type="Drug"><TargetEntity id="295011" type="siDrug">Ozarelix</TargetEntity></SourceEntity><SourceEntity id="15623" type="Company"><TargetEntity id="4296603039" type="organizationId">Asta Medica AG</TargetEntity></SourceEntity><SourceEntity id="18535" type="Company"><TargetEntity id="4295876918" type="organizationId">Nippon Kayaku Co Ltd</TargetEntity></SourceEntity><SourceEntity id="22711" type="Company"><TargetEntity id="4295862603" type="organizationId">Aeterna Zentaris Inc</TargetEntity></SourceEntity><SourceEntity id="24232" type="Company"><TargetEntity id="4295907365" type="organizationId">Spectrum Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="29069" type="Company"><TargetEntity id="5000760039" type="organizationId">Aeterna Zentaris GmbH</TargetEntity></SourceEntity><SourceEntity id="29750" type="Company"><TargetEntity id="4297886212" type="organizationId">Baxter Oncology GmbH</TargetEntity></SourceEntity><SourceEntity id="113" type="ciIndication"><TargetEntity id="N80" type="ICD10"></TargetEntity><TargetEntity id="617.0" type="ICD9"></TargetEntity><TargetEntity id="10014778" type="MEDDRA"></TargetEntity><TargetEntity id="D004715" type="MeSH"></TargetEntity><TargetEntity id="-1297427982" type="omicsDisease"></TargetEntity><TargetEntity id="546" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1241" type="ciIndication"><TargetEntity id="10051482" type="MEDDRA"></TargetEntity><TargetEntity id="D011470" type="MeSH"></TargetEntity><TargetEntity id="-1410482198" type="omicsDisease"></TargetEntity><TargetEntity id="362" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="14" type="ciIndication"><TargetEntity id="G30" type="ICD10"></TargetEntity><TargetEntity id="331.0" type="ICD9"></TargetEntity><TargetEntity id="10012271" type="MEDDRA"></TargetEntity><TargetEntity id="D000544" type="MeSH"></TargetEntity><TargetEntity id="-1268969445" type="omicsDisease"></TargetEntity><TargetEntity id="101" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="276" type="ciIndication"><TargetEntity id="C61" type="ICD10"></TargetEntity><TargetEntity id="10060862" type="MEDDRA"></TargetEntity><TargetEntity id="D011471" type="MeSH"></TargetEntity><TargetEntity id="-405461207" type="omicsDisease"></TargetEntity><TargetEntity id="5083" type="siCondition"></TargetEntity><TargetEntity id="637" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="799" type="ciIndication"><TargetEntity id="C56" type="ICD10"></TargetEntity><TargetEntity id="10033128" type="MEDDRA"></TargetEntity><TargetEntity id="D010051" type="MeSH"></TargetEntity><TargetEntity id="-1370909262" type="omicsDisease"></TargetEntity><TargetEntity id="626" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity></SourceEntity><SourceEntity id="455" type="Action"><TargetEntity id="589" type="Mechanism">GnRH (LHRH) Antagonists</TargetEntity><TargetEntity id="2681" type="Mechanism">Anti-LHRH</TargetEntity><TargetEntity id="4654" type="Mechanism">Anti-Gonadotropin Releasing Hormone (GnRH)</TargetEntity></SourceEntity><SourceEntity id="60" type="Action"><TargetEntity id="1746" type="Mechanism">Androgen Receptor Antagonists</TargetEntity></SourceEntity><SourceEntity id="PTGT-00135" type="ciTarget"><TargetEntity id="9904399853673" type="siTarget">Androgen receptor</TargetEntity><TargetEntity id="4423" type="omicsTarget"></TargetEntity></SourceEntity><SourceEntity id="PTGT-00881" type="ciTarget"><TargetEntity id="14970030727983" type="siTarget">Gonadotropin-releasing hormone receptor</TargetEntity><TargetEntity id="2775" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="C2">Phase 2 Clinical</PhaseHighest><IndicationsPrimary><Indication id="113">Endometriosis</Indication><Indication id="276">Prostate tumor</Indication><Indication id="3247">Hormone dependent prostate cancer</Indication><Indication id="799">Ovary tumor</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="1241">Prostate hyperplasia</Indication><Indication id="14">Alzheimers disease</Indication></IndicationsSecondary><ActionsPrimary><Action id="455">GNRH receptor antagonist</Action><Action id="60">Androgen receptor antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="1545">Anticancer</Action><Action id="1615">Neuroprotectant</Action></ActionsSecondary><Technologies><Technology id="589">Sustained release formulation</Technology><Technology id="647">Subcutaneous formulation</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="80">Peptide</Technology><Technology id="651">Intramuscular formulation</Technology></Technologies><EphmraCodes><Ephmra><Code>H1C3</Code><Name>Antigonadotrophin-releasing hormones</Name></Ephmra><Ephmra><Code>G4C</Code><Name>BPH (benign prostatic hypertrophy) products </Name></Ephmra></EphmraCodes><LastModificationDate>2019-03-22T19:40:49.000Z</LastModificationDate><ChangeDateLast>2018-09-20T00:00:00.000Z</ChangeDateLast><AddedDate>2001-06-20T15:28:59.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="24232" linkType="Company"&gt;Spectrum&lt;/ulink&gt; under license from &lt;ulink linkID="22711" linkType="Company"&gt;AEterna Zentaris&lt;/ulink&gt; (formerly Zentaris), which previously aquired the drug from &lt;ulink linkID="15628" linkType="Company"&gt;ASTA&lt;/ulink&gt;,  is developing intramuscular and subcutaneous formulations of ozarelix  (D-63153; SPI-153; AEZS-106), a &lt;ulink linkID="23220" linkType="Drug"&gt;D-26344&lt;/ulink&gt;  analog, that acts as a decapeptide LHRH antagonist and  supressor of testosterone and pituitary hormones,  for the  potential treatment of hormone-dependent prostate cancer (HDPC). Ozarelix is also being investigated by Spectrum for the potential treatment of endometriosis and ovarian cancer [&lt;ulink linkID="412889" linkType="reference"&gt;412889&lt;/ulink&gt;], [&lt;ulink linkID="459775" linkType="reference"&gt;459775&lt;/ulink&gt;], [&lt;ulink linkID="554249" linkType="Reference"&gt;554249&lt;/ulink&gt;], [&lt;ulink linkID="1092205" linkType="Reference"&gt;1092205&lt;/ulink&gt;], [&lt;ulink linkID="1247177" linkType="Reference"&gt;1247177&lt;/ulink&gt;].   A licensee &lt;ulink linkID="18535" linkType="Company"&gt;Nippon Kayaku&lt;/ulink&gt; is  investigating the drug in Japan for HDPC  [&lt;ulink linkID="681832" linkType="Reference"&gt;681832&lt;/ulink&gt;], [&lt;ulink linkID="682038" linkType="Reference"&gt;682038&lt;/ulink&gt;]. In July 2005, a phase I/II program in HDPC began in the US [&lt;ulink linkID="613888" linkType="Reference"&gt;613888&lt;/ulink&gt;]; in August 2012, a phase IIb trial was underway in the US and India [&lt;ulink linkID="1315446" linkType="Reference"&gt;1315446&lt;/ulink&gt;]; in December 2014, the trial was ongoing  [&lt;ulink linkID="1616721" linkType="Reference"&gt;1616721&lt;/ulink&gt;]. In September 2011, development was ongoing for Endometriosis  and  ovarian cancer  by Spectrum [&lt;ulink linkID="1220031" linkType="Reference"&gt;1220031&lt;/ulink&gt;]. In June 2015, development was ongoing by  Nippon Kayaku [&lt;ulink linkID="1668551" linkType="Reference"&gt;1668551&lt;/ulink&gt;]. In April 2010, Spectrum was seeking to outlicense the drug in India [&lt;ulink linkID="1092205" linkType="Reference"&gt;1092205&lt;/ulink&gt;]; in June 2015, Spectrum was seeking to outlicense the drug within its territory [&lt;ulink linkID="1670009" linkType="Reference"&gt;1670009&lt;/ulink&gt;]. In September 2018, the company was seeking to outlicense the drug outside the US such as Europe and Asia [&lt;ulink linkID="2074148" linkType="Reference"&gt;2074148&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="29750" linkType="Company"&gt;Baxter&lt;/ulink&gt; was previously developing the drug for prostate tumor [&lt;ulink linkID="476077" linkType="Reference"&gt;476077&lt;/ulink&gt;]; however, the company passed back all rights to Zentaris in August 2004 [&lt;ulink linkID="554249" linkType="Reference"&gt;554249&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;AEterna Zentaris was developing the drug for HDPC. In April 2005,  European phase II trials in HDPC began  [&lt;ulink linkID="594390" linkType="Reference"&gt;594390&lt;/ulink&gt;], [&lt;ulink linkID="594456" linkType="Reference"&gt;594456&lt;/ulink&gt;];  in August 2006, positive results were reported and a European phase IIb HDPC trial was initiated  [&lt;ulink linkID="681524" linkType="Reference"&gt;681524&lt;/ulink&gt;], [&lt;ulink linkID="681537" linkType="Reference"&gt;681537&lt;/ulink&gt;]. In January 2006, AEterna Zentaris was seeking to outlicense worldwide codevelopment rights to ozarelix except in North America and India [&lt;ulink linkID="651260" linkType="Reference"&gt;651260&lt;/ulink&gt;]. However, in June 2015, the company disclosed that it was not pursuing the development of ozarelix [&lt;ulink linkID="1668551" linkType="Reference"&gt;1668551&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;AEterna Zentaris was previously investigating the drug for endometriosis; however, no further development has been reported for this indication since August 2004 [&lt;ulink linkID="554249" linkType="Reference"&gt;554249&lt;/ulink&gt;]. Spectrum and AEterna Zentaris were previously developing the drug for benign prostatic hypertrophy (BPH). In April 2005, AEterna Zentaris initiated a phase II trial [&lt;ulink linkID="594899" linkType="Reference"&gt;594899&lt;/ulink&gt;]. In May 2007, Health Canada approved Spectrum's CTA for pivotal phase III BPH trials. The studies were to start in late 2007 [&lt;ulink linkID="790562" linkType="Reference"&gt;790562&lt;/ulink&gt;]. By November 2007, the company was planning and designing a registrational trial, which was  to start in early  2008 [&lt;ulink linkID="849626" linkType="Reference"&gt;849626&lt;/ulink&gt;]. However, development was discontinued  for this indication in January 2010, following disappointing phase IIb study results [&lt;ulink linkID="1071127" linkType="Reference"&gt;1071127&lt;/ulink&gt;].  AEterna Zentaris was previously developing the drug for  Alzheimer’s disease.  In December 2007, a phase II study was completed in Germany [&lt;ulink linkID="1444104" linkType="Reference"&gt;1444104&lt;/ulink&gt;]. However, no further development had been reported since December 2007.&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Benign prostatic hypertrophy&lt;/subtitle&gt;In September 2008, a multi-center, randomized, double-blind, placebo-controlled phase II trial (&lt;ulink linkID="34286" linkType="Protocol"&gt;NCT00743184&lt;/ulink&gt;; SPI-153-08-1) began in subjects (expected n = 860) with BPH. At that time, the trial was estimated to complete in  August 2011 [&lt;ulink linkID="1096393" linkType="Reference"&gt;1096393&lt;/ulink&gt;]; however the trial was terminated in February 2010 [&lt;ulink linkID="1096393" linkType="Reference"&gt;1096393&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2007, Health Canada approved Spectrum's CTA for pivotal phase III BPH trials. The studies were to start in late 2007 [&lt;ulink linkID="790562" linkType="Reference"&gt;790562&lt;/ulink&gt;]. In May 2007, a phase III BPH trial was expected to begin in the second half of 2007 [&lt;ulink linkID="798235" linkType="Reference"&gt;798235&lt;/ulink&gt;], [&lt;ulink linkID="798238" linkType="Reference"&gt;798238&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2007, Spectrum received FDA approval to start  a phase IIb trial  (&lt;ulink linkID="21086" linkType="Protocol"&gt;NCT00427219&lt;/ulink&gt;; SPI-153-06-1) later that month. In the randomized, placebo-controlled trial, 100 men would receive 15 mg of ozarelix on day 1 and 15 and would be assessed for 6 months. The primary endpoint was improvement of BPH symptoms as measured by the international prostate symptom score (IPSS). The study would also measure urine flow, residual urine volume and quality of life. Safety and efficacy data from the trial would support an NDA for ozarelix. At that time, data were expected to be reported in June 2007 and phase III trials were scheduled to begin in the second half of 2007, testing the long term safety of ozarelix courses given at 6 month intervals [&lt;ulink linkID="754751" linkType="Reference"&gt;754751&lt;/ulink&gt;], [&lt;ulink linkID="760276" linkType="Reference"&gt;760276&lt;/ulink&gt;]. In January 2007, Spectrum began dosing in the  US, phase IIb trial [&lt;ulink linkID="760276" linkType="Reference"&gt;760276&lt;/ulink&gt;]; in March 2007, the trial was expected to be completed in the second half of 2007  [&lt;ulink linkID="774278" linkType="Reference"&gt;774278&lt;/ulink&gt;]. The company completed enrollment in May 2007 and expected to report results in the second half of 2007 [&lt;ulink linkID="789131" linkType="Reference"&gt;789131&lt;/ulink&gt;]. The phase IIb trial was being conducted in the US and Canada [&lt;ulink linkID="821872" linkType="Reference"&gt;821872&lt;/ulink&gt;]. In November 2007, results were expected in the second quarter of 2008 [&lt;ulink linkID="849626" linkType="Reference"&gt;849626&lt;/ulink&gt;]. In April 2008, Spectrum reported from the phase IIb trial  that ozarelix demonstrated sufficient activity to be proceeded into phase III. At that time, the company was planning to submit a protocol to the FDA for the following trial [&lt;ulink linkID="898977" linkType="Reference"&gt;898977&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2006, at the 28th Congress of the Societe Internationale d'Urologie in Cape Town, South Africa, data were presented from Spectrum's phase II double-blind, randomized, placebo controlled, dose ranging trial with ozarelix in BPH patients. All dose regimes were well tolerated, with the most effective dose being 15 mg on days 1 and 15 of the trial, in terms of a significant improvement in the international prostate symptom score (IPSS), versus baseline and placebo IPSS scores [&lt;ulink linkID="760276" linkType="Reference"&gt;760276&lt;/ulink&gt;]. Similar data were presented at the 29th Congress of the Societe Internationale d'Urologie in Paris, France in September 2007 [&lt;ulink linkID="827754" linkType="Reference"&gt;827754&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2005, double-blind, placebo-controlled, multicenter phase II trial began in BPH. The study was to evaluate the effects of ozarelix on signs and symptoms of BPH using the international prostate symptom score and maximum uroflow. The durability of response would also be assessed over several months [&lt;ulink linkID="594886" linkType="Reference"&gt;594886&lt;/ulink&gt;], [&lt;ulink linkID="594899" linkType="Reference"&gt;594899&lt;/ulink&gt;]. In November 2005, AEterna Zentaris completed enrollment of the trial 4 months ahead of schedule [&lt;ulink linkID="636090" linkType="Reference"&gt;636090&lt;/ulink&gt;]. In October 2006, AEterna Zentaris reported that the trial  had met its primary and secondary endpoints. The full results were to  be presented in 2007. The European study treated 144 patients with 5, 10, 15 or 20 mg of the drug, or placebo, im on days 1 and 15. All dose levels of ozarelix met the primary endpoint of IPSS at week 12 and the improvement also persisted out to week 28. A 47% mean improvement was seen in the 15 mg dose group.  The secondary endpoints of uroflow, residual urinary volume, quality of life, and circulating testosterone levels also showed good results, especially in the 15 mg dose group. The drug had no serious side effects and did not affect erectile function [&lt;ulink linkID="723555" linkType="Reference"&gt;723555&lt;/ulink&gt;], [&lt;ulink linkID="720929" linkType="Reference"&gt;720929&lt;/ulink&gt;]. In May 2007, similar data were presented at the American Urological Association annual meeting in Anaheim, CA [&lt;ulink linkID="798235" linkType="Reference"&gt;798235&lt;/ulink&gt;], [&lt;ulink linkID="798238" linkType="Reference"&gt;798238&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Prostate cancer&lt;/subtitle&gt;In August 2012, patient enrollment was initiated in the second part of a randomized, open-label, phase IIb (&lt;ulink linkID="72767" linkType="Protocol"&gt;NCT01252693&lt;/ulink&gt;; SPI-153-10-1) study to assess the safety and efficacy of a monthly dosing regimen of sc ozarelix compared with &lt;ulink linkID="7286" linkType="Drug"&gt;Zoladex&lt;/ulink&gt; depot. A total of 150 patients were to be recruited in the US and India [&lt;ulink linkID="1315446" linkType="Reference"&gt;1315446&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2006, a European phase IIb trial was initiated. It was to assess a 130 mg dose of ozarelix in 32 patients [&lt;ulink linkID="681524" linkType="Reference"&gt;681524&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Also in August 2006,  a Japanese phase I trial was planned for  early 2007 [&lt;ulink linkID="685564" linkType="Reference"&gt;685564&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2005, a US phase I/II program began [&lt;ulink linkID="613888" linkType="Reference"&gt;613888&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2005, a multicenter, European, phase II trial  began in hormone-dependent prostate cancer patients to evaluate the effects of ozarelix on hormonal levels, as well as objective antitumor effects [&lt;ulink linkID="594390" linkType="Reference"&gt;594390&lt;/ulink&gt;], [&lt;ulink linkID="594456" linkType="Reference"&gt;594456&lt;/ulink&gt;]. In August 2005, enrollment was completed 4 months ahead of schedule: at that time, no allergic reactions had been reported [&lt;ulink linkID="619936" linkType="Reference"&gt;619936&lt;/ulink&gt;], [&lt;ulink linkID="619961" linkType="Reference"&gt;619961&lt;/ulink&gt;]. In August 2006, AEterna reported that ozarelix had met its primary and secondary endpoints of testosterone suppression and PSA reduction. The open-label, randomized, controlled dose-finding trial assessed the safety and efficacy of 65, 100 and 130 mg of ozarelix in 64 patients. They received different dosing schedules for three cycles of 28 days each. The 130 mg dose was found to suppress testosterone to castration level until at least day 85. Tumor response, as measured by PSA levels, was 97% in patients with continuous testosterone suppression below castration level. The drug was also well tolerated. Further data were to be presented later in 2006 [&lt;ulink linkID="681524" linkType="Reference"&gt;681524&lt;/ulink&gt;], [&lt;ulink linkID="681537" linkType="Reference"&gt;681537&lt;/ulink&gt;]. In November 2006, similar data were presented at the 28th Congress of the Societe Internationale d'Urologie in Cape Town, South Africa [&lt;ulink linkID="741246" linkType="Reference"&gt;741246&lt;/ulink&gt;], [&lt;ulink linkID="742060" linkType="Reference"&gt;742060&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Phase II studies in prostate cancer were reportedly underway by January 2003 [&lt;ulink linkID="476077" linkType="reference"&gt;476077&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Alzheimer’s disease&lt;/subtitle&gt;In December 2007, a randomized, double-blind, parallel group, placebo-controlled, phase II study (&lt;ulink linkID="142606" linkType="Protocol"&gt;ZEN-006-Z030&lt;/ulink&gt;; EudraCT 2004-005001-29) was completed in male patients (n = 140) with mild to moderate Alzheimer’s disease, in Germany [&lt;ulink linkID="1444104" linkType="Reference"&gt;1444104&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Endometriosis&lt;/subtitle&gt;In March 2006, an European study in healthy female volunteers for       endometriosis was being planned for  the second half of 2006 [&lt;ulink linkID="655624" linkType="Reference"&gt;655624&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I data&lt;/subtitle&gt;By 2003, two phase I trials had been completed. One was a single-dose, dose escalation trial using an immediate release formulation. The other was a single-dose, dose escalation trial using 10, 30 or 60 mg ozarelix in a long-acting formulation injected im. The 60 mg sustained-release dose induced castration for 1 month in healthy male volunteers [&lt;ulink linkID="500279" linkType="reference"&gt;500279&lt;/ulink&gt;],  [&lt;ulink linkID="594456" linkType="Reference"&gt;594456&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In November 2002, preclinical data on ozarelix were presented at the 14th EORTC-NCI-AACR meeting in Frankfurt, Germany. In rats and dogs, ozarelix resulted in dose-dependent LH and testosterone suppression. In castrated rats,  subcutaneous (sc) ozarelix resulted in near undetectable levels of LH plasma. Duration of suppression was dose-dependent. Ozarelix (sc) evoked a long-lasting complete abrogation of testosterone production in rats. A loading dose/maintenance dose schedule resulted in castration testosterone levels over the complete treatment period. Atrophy of gonadal organs was almost completely reversible 40 days after treatment termination. Tumor growth in different animal models was suppressed in a dose-dependent manner. Duration of tumor inhibition was dose-dependent [&lt;ulink linkID="470660" linkType="reference"&gt;470660&lt;/ulink&gt;]. In the radioligand displacement binding assay, ozarelix bound to human and rat GnRH receptor with a KD value of 0.19  and 0.045 nM, respectively [&lt;ulink linkID="470660" linkType="reference"&gt;470660&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The compound demonstrated in vitro affinity at the GnRH receptor in the pM range. In comparison to &lt;ulink linkID="6817" linkType="Drug"&gt;cetrorelix&lt;/ulink&gt;  it had improved physicochemical properties and a relatively long lasting suppression of testosterone was found in vivo. ozarelix had a high solubility in water resulting in a high potential for a depot formulation [&lt;ulink linkID="412889" linkType="reference"&gt;412889&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;By November 2008, &lt;ulink linkID="19986" linkType="Company"&gt;Handok Pharmaceuticals&lt;/ulink&gt;  had acquired  rights  to market ozarelix for  BPH in   Korea [&lt;ulink linkID="962805" linkType="Reference"&gt;962805&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2006, AEterna Zentaris  licensed the Japanese oncology development and marketing rights to ozarelix to Nippon Kayaku [&lt;ulink linkID="681832" linkType="Reference"&gt;681832&lt;/ulink&gt;], [&lt;ulink linkID="682038" linkType="Reference"&gt;682038&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2004, Zentaris granted Spectrum Pharmaceuticals an exclusive license to develop and commercialize ozarelix for all potential indications in North America (including Canada and Mexico) and India.  Zentaris retained exclusive rights to the rest of world and would share upfront and milestone payments, royalties or profits from potential sales in Japan with Spectrum [&lt;ulink linkID="554249" linkType="Reference"&gt;554249&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By January 2002, Zentaris had  inherited ozarelix following the break-up of ASTA Medica [&lt;ulink linkID="435379" linkType="Reference"&gt;435379&lt;/ulink&gt;]. Baxter Oncology licensed all rights to ozarelix in cancer from Zentaris by June 2002 [&lt;ulink linkID="454757" linkType="Reference"&gt;454757&lt;/ulink&gt;]. In February 2003, Baxter gained rights to the compound in all other indications [&lt;ulink linkID="478828" linkType="Reference"&gt;478828&lt;/ulink&gt;], [&lt;ulink linkID="500271" linkType="Reference"&gt;500271&lt;/ulink&gt;]. In August 2004, Zentaris regained worldwide rights to ozarelix from Baxter as a result of organizational changes and restructuring at Baxter, and following a mutual understanding between the two companies aimed at maximizing the value of the drug [&lt;ulink linkID="554249" linkType="Reference"&gt;554249&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="24232">Spectrum Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3247">Hormone dependent prostate cancer</Indication><StatusDate>2005-07-25T00:00:00.000Z</StatusDate><Source id="613888" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24232">Spectrum Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="113">Endometriosis</Indication><StatusDate>2004-08-12T00:00:00.000Z</StatusDate><Source id="554249" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24232">Spectrum Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate>2010-04-21T00:00:00.000Z</StatusDate><Source id="1092205" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18535">Nippon Kayaku Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="276">Prostate tumor</Indication><StatusDate>2006-08-03T00:00:00.000Z</StatusDate><Source id="681832" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24232">Spectrum Pharmaceuticals Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1241">Prostate hyperplasia</Indication><StatusDate>2010-01-27T00:00:00.000Z</StatusDate><Source id="1071127" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24232">Spectrum Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1241">Prostate hyperplasia</Indication><StatusDate>2010-01-27T00:00:00.000Z</StatusDate><Source id="1071127" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29750">Baxter Oncology GmbH</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3247">Hormone dependent prostate cancer</Indication><StatusDate>2004-08-12T00:00:00.000Z</StatusDate><Source id="554249" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22711">AEterna Zentaris Inc</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="113">Endometriosis</Indication><StatusDate>2006-02-13T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24232">Spectrum Pharmaceuticals Inc</Company><Country id="IN">India</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="3247">Hormone dependent prostate cancer</Indication><StatusDate>2014-02-14T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22711">AEterna Zentaris Inc</Company><Country id="DE">Germany</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate>2009-06-17T00:00:00.000Z</StatusDate><Source id="1444104" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22711">AEterna Zentaris Inc</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1241">Prostate hyperplasia</Indication><StatusDate>2010-01-27T00:00:00.000Z</StatusDate><Source id="1071127" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22711">AEterna Zentaris Inc</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3247">Hormone dependent prostate cancer</Indication><StatusDate>2015-06-09T00:00:00.000Z</StatusDate><Source id="1668551" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="22711">AEterna Zentaris Inc</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate>2007-12-17T00:00:00.000Z</StatusDate><Source id="1444104" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22711">AEterna Zentaris Inc</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3247">Hormone dependent prostate cancer</Indication><StatusDate>2005-04-11T00:00:00.000Z</StatusDate><Source id="594390" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24232">Spectrum Pharmaceuticals Inc</Company><Country id="IN">India</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3247">Hormone dependent prostate cancer</Indication><StatusDate>2012-08-14T00:00:00.000Z</StatusDate><Source id="1315446" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15623">ASTA Medica AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="276">Prostate tumor</Indication><StatusDate>2001-06-20T00:00:00.000Z</StatusDate><Source id="412889" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29069">Zentaris GmbH</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="276">Prostate tumor</Indication><StatusDate>2002-01-14T00:00:00.000Z</StatusDate><Source id="435767" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29069">Zentaris GmbH</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="276">Prostate tumor</Indication><StatusDate>2001-06-20T00:00:00.000Z</StatusDate><Source id="435379" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29750">Baxter Oncology GmbH</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="276">Prostate tumor</Indication><StatusDate>2001-11-01T00:00:00.000Z</StatusDate><Source id="454311" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29750">Baxter Oncology GmbH</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="276">Prostate tumor</Indication><StatusDate>2003-01-13T00:00:00.000Z</StatusDate><Source id="476077" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29069">Zentaris GmbH</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><Indication id="276">Prostate tumor</Indication><StatusDate>2002-06-14T00:00:00.000Z</StatusDate><Source id="476670" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24232">Spectrum Pharmaceuticals Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="276">Prostate tumor</Indication><StatusDate>2005-03-15T00:00:00.000Z</StatusDate><Source id="589802" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22711">AEterna Zentaris Inc</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1241">Prostate hyperplasia</Indication><StatusDate>2004-08-12T00:00:00.000Z</StatusDate><Source id="554249" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24232">Spectrum Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="276">Prostate tumor</Indication><StatusDate>2004-08-12T00:00:00.000Z</StatusDate><Source id="554249" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24232">Spectrum Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1241">Prostate hyperplasia</Indication><StatusDate>2004-08-12T00:00:00.000Z</StatusDate><Source id="554249" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24232">Spectrum Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1241">Prostate hyperplasia</Indication><StatusDate>2004-08-12T00:00:00.000Z</StatusDate><Source id="760276" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24232">Spectrum Pharmaceuticals Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1241">Prostate hyperplasia</Indication><StatusDate>2007-08-14T00:00:00.000Z</StatusDate><Source id="821872" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22711">AEterna Zentaris Inc</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1241">Prostate hyperplasia</Indication><StatusDate>2005-04-13T00:00:00.000Z</StatusDate><Source id="594899" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22711">AEterna Zentaris Inc</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="113">Endometriosis</Indication><StatusDate>2004-08-12T00:00:00.000Z</StatusDate><Source id="554249" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00135"><Name>Androgen receptor</Name><SwissprotNumbers><Swissprot>O97775</Swissprot><Swissprot>O97776</Swissprot><Swissprot>O97952</Swissprot><Swissprot>O97960</Swissprot><Swissprot>P10275</Swissprot><Swissprot>P15207</Swissprot><Swissprot>P19091</Swissprot><Swissprot>P49699</Swissprot><Swissprot>Q6QT55</Swissprot><Swissprot>Q7T1K4</Swissprot><Swissprot>Q8MIK0</Swissprot><Swissprot>Q9GKL7</Swissprot><Swissprot>Q9TT90</Swissprot></SwissprotNumbers></Target><Target id="PTGT-00881"><Name>GNRH receptor</Name><SwissprotNumbers><Swissprot>O18821</Swissprot><Swissprot>O42329</Swissprot><Swissprot>P30968</Swissprot><Swissprot>P30969</Swissprot><Swissprot>P32236</Swissprot><Swissprot>P32237</Swissprot><Swissprot>P49922</Swissprot><Swissprot>Q01776</Swissprot><Swissprot>Q8CH60</Swissprot><Swissprot>Q8SPZ1</Swissprot><Swissprot>Q95JG1</Swissprot><Swissprot>Q95MG6</Swissprot><Swissprot>Q95MH6</Swissprot><Swissprot>Q96P88</Swissprot><Swissprot>Q9MZI6</Swissprot><Swissprot>Q9TTI8</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1036094">Evonik Industries AG</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="14437">Baxter International Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="18535">Nippon Kayaku Co Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="19986">Handok Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="22711">AEterna Zentaris Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>5</CountTotal></Company><Company><Company id="24232">Spectrum Pharmaceuticals Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="14">Drug - Asset Divestment</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>2</CountActive><CountInactive>1</CountInactive><CountTotal>3</CountTotal></Type><Type><Type sortOrder="5">Drug - Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>CCCC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(=O)N)NC(=O)[C@@H](CCCCNC(=O)N)NC(=O)[C@H](Cc2ccc(cc2)O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](Cc3cccnc3)NC(=O)[C@@H](Cc4ccc(cc4)Cl)NC(=O)[C@@H](Cc5ccc6ccccc6c5)NC(=O)C</Smiles></StructureSmiles><Deals><Deal id="107278" title="Spectrum to develop AEterna Zentaris' ozarelix in North America, Mexico and India "/><Deal id="109135" title="Nippon Kayaku to develop AEterna Zentaris' ozarelix for cancer in Japan  "/><Deal id="110060" title="Baxter Oncology to develop Zentaris' ozarelix for cancer"/><Deal id="116914" title="AEterna Zentaris to obtain rights to ASTA Medica's ozarelix and cetrorelix"/><Deal id="119046" title="Handok to market AEterna's ozarelix for benign prostatic hypertrophy in Korea and other Asian countries excluding Japan"/></Deals><PatentFamilies><PatentFamily id="1320892" number="WO-2006069641" title="Method for producing sterile suspensions or lyophilisates of poorly soluble basic peptide complexes,n pharmaceutical formulations containing the same, and use thereof as medicaments"/><PatentFamily id="1521964" number="WO-00055190" title="Novel LHRH antagonists with improved solubility characteristics"/><PatentFamily id="1679031" number="WO-03045419" title="Injection solution comprising an LHRH antagonist"/><PatentFamily id="1829332" number="WO-02102401" title="Treatment of dementia and neurodegenerative diseases with intermediate doses of lhrh antagonists"/><PatentFamily id="1959320" number="WO-2008017664" title="Application of initial doses of lhrh analogues and maintenance doses of lhrh antagonists for the treatement of hormone-dependent cancers and corresponding pharmaceutical kits"/><PatentFamily id="2027487" number="WO-00168676" title="Novel LHRH-antagonists, production and use thereof as a medicament"/><PatentFamily id="2324912" number="WO-2004030650" title="Administration form for pharmaceutically active peptides with sustained release and method for the production thereof"/><PatentFamily id="367869" number="EP-02266568" title="Use of LHRH antagonists in combination with PDE V inhibitors for the treatment of sex hormone dependent disorders"/><PatentFamily id="516502" number="WO-2008107446" title="Use of LHRH antagonists for the treatment of lower urinary tract symptoms, in particular overactive bladder and/or detrusor overactivity"/><PatentFamily id="55633" number="WO-00121194" title="Method For The Therapeutic Management Of Extrauterine Proliferation Of Endometrial Tissue, Chronic Pelvic Pain And Fallopian Tube Obstruction"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>5</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>2</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sanofi SA" id="1009547"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Evonik Industries AG" id="1036094"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Baxter International Inc" id="14437"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="AEterna Zentaris Inc" id="22711"/><CountAsOwner>10</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>10</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>